Clinical Trials
10 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05172258 2026-05-13
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02581137 2026-04-13
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05075980 2026-04-13
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
Phase 2 Active not recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04862650 2026-02-10
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05312710 2026-01-16
Safety and Efficacy of APG-157 in Head and Neck Cancer
Aveta Biomics, Inc.
Phase 2 Active not recruiting
NCT03383094 2025-10-07
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Phase 2 Active not recruiting
NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06728631 2025-02-24
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Active not recruiting